Cvs Health Corp

CVS generates revenue through operating retail pharmacies selling prescriptions and front-store merchandise, managing pharmacy benefits as a PBM (Caremark), and providing health insurance through Aetna. The company makes money from prescription drug dispensing margins, PBM fees and rebates, insurance premiums, and retail product sales. CVS operates an integrated healthcare model connecting insurance, pharmacy benefits, retail pharmacies, and MinuteClinic health services to manage costs and improve patient outcomes across the healthcare continuum.

CVS offers exposure to pharmacy and healthcare services with integrated capabilities across insurance, PBM, and retail. The company benefits from prescription volume growth, aging demographics, and chronic disease management opportunities. Strengths include market leadership and care delivery integration. Risks include PBM margin pressures, retail pharmacy reimbursement challenges, Medicare Advantage competition, integration complexity from Aetna acquisition, and regulatory scrutiny of pharmacy pricing. The stock trades at discounted valuations with dividend yield.

CVS competes with Walgreens Boots Alliance in retail pharmacy and clinic services. UnitedHealth Group competes across health insurance and PBM through OptumRx. Cigna operates Express Scripts PBM competing for employer clients. Walmart and Amazon Pharmacy compete in prescription dispensing with lower-cost models. In Medicare Advantage, CVS competes with Humana, UnitedHealth, and regional insurers. Competition varies significantly across CVS's different business segments.

CVS pays a quarterly dividend yielding approximately 3.48%, demonstrating commitment to shareholder returns while investing in healthcare integration. The company has maintained its dividend through challenges including the Aetna acquisition, supported by cash flows from retail pharmacy and insurance operations. CVS balances dividend payments with debt reduction and strategic investments in primary care and digital health capabilities. The dividend provides income while management works to realize synergies from its integrated healthcare model.

CVS last closed at $72.80, up 2.12% in the most recent trading session. Over the past 52 weeks, the stock has traded between a low of $58.35 and a high of $85.15. The current price represents 54% of its 52-week range, which helps investors gauge where the stock sits relative to its recent trading history.

Among 33 analysts covering CVS, the consensus rating is Strong Buy — 25 rate it a buy, 8 hold, and 0 sell. The average price target sits at $162.09, implying 123% upside from the current price. Keep in mind that analyst targets reflect 12-month expectations and can shift quickly after earnings reports or major company events.

Cvs Health Corp generated $403.80B in revenue during fiscal year 2026, with $1.78B reaching the bottom line as net income. The net profit margin of 0.4% reflects the competitive nature of its industry.

CVS trades at a P/E ratio of 51.61 on trailing earnings of $1.37 per share. That's well above the S&P 500 historical average of ~20-25x, which typically signals that investors are pricing in aggressive future growth. Comparing this multiple against Health Care sector peers gives better context than the broad market alone, since P/E norms vary significantly across industries.

Performance varies across timeframes, reflecting shifting market conditions. Returns by timeframe: -8.55% (3M), -3.92% (6M), +9.51% (1Y), -9.15% (YTD). Comparing these figures against the S&P 500 and sector benchmarks helps determine whether CVS is outperforming or lagging the broader market.